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A B S T R A C T
Fatty acid oxidation is a central fueling pathway for mitochondrial ATP production. Regulation occurs through
multiple nutrient- and energy-sensitive molecular mechanisms. We explored if upregulated mRNA expression of
the mitochondrial enzyme pyruvate dehydrogenase kinase 4 (PDK4) may be used as a surrogate marker of
increased mitochondrial fatty acid oxidation, by indicating an overall shift from glucose to fatty acids as the
preferred oxidation fuel. The association between fatty acid oxidation and PDK4 expression was studied in
different contexts of metabolic adaption. In rats treated with the modified fatty acid tetradecylthioacetic acid
(TTA), Pdk4 was upregulated simultaneously with fatty acid oxidation genes in liver and heart, whereas muscle
and white adipose tissue remained unaffected. In MDA-MB-231 cells, fatty acid oxidation increased nearly three-
fold upon peroxisome proliferator-activated receptor α (PPARα, PPARA) overexpression, and four-fold upon
TTA-treatment. PDK4 expression was highly increased under these conditions. Further, overexpression of PDK4
caused increased fatty acid oxidation in these cells. Pharmacological activators of PPARα and AMPK had minor
effects, while the mTOR inhibitor rapamycin potentiated the effect of TTA. There were minor changes in mi-
tochondrial respiration, glycolytic function, and mitochondrial biogenesis under conditions of increased fatty
acid oxidation. TTA was found to act as a mild uncoupler, which is likely to contribute to the metabolic effects.
Repeated experiments with HeLa cells supported these findings. In summary, PDK4 upregulation implies an
overarching metabolic shift towards increased utilization of fatty acids as energy fuel, and thus constitutes a
sensitive marker of enhanced fatty acid oxidation.
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Mitochondrial fatty acid oxidation is a crucial and highly regulated
fueling pathway for aerobic ATP production in mammalian organisms.
Abnormalities of mitochondrial fatty acid oxidation affects diverse
cellular and systemic functions, and have been linked to conditions
such as diabetes, metabolic syndrome, cancer, cancer cachexia, neu-
rodegeneration and ME/CFS (Naviaux et al., 2016; Germain et al.,
2017; Rohlenova et al., 2018; Adeva-Andany et al., 2018; Fukawa et al.,
2016). Functional analysis of mitochondrial fatty acid oxidation in
conventional biopsies are difficult, partly since it requires viable cells or
non-frozen tissue samples. Identification of sensitive and effective sur-
rogate markers of mitochondrial fatty acid oxidation may thus provide
new opportunities to assess (patho)physiological effects on metabolism.
Fatty acid catabolism is co-regulated with other pathways of cell me-
tabolism to support homeostasis when the energy supply or demand
change. There is a well-established concept of reciprocal regulation
between fatty acid and glucose oxidation for energy purposes. Different
types of metabolic adaptations may occur to accommodate (patho)
physiological changes (Sugden and Holness, 1994; Trexler et al., 2014;
Jose et al., 2013). The pyruvate dehydrogenase (PDH) complex and the
carnitine palmitoyltransferase (CPT) system are important in this con-
text. PDH converts pyruvate from glycolysis to acetyl-CoA and CO2
through oxidative decarboxylation, whereas the CPT system transports
fatty acids into mitochondria, a rate-limiting process for acetyl-CoA
production by mitochondrial fatty acid oxidation. PDH and the CPT
system are both regulated in response to changing energy conditions,
partly through contextual nutrient-gene and nutrient-protein interac-
tions that leads to metabolic adaptations. Increased rates of fatty acid
oxidation, e.g. due to starvation or insulin-deficient diabetes, is asso-
ciated with suppression of PDH activity (reviewed in (Holness and
Sugden, 2003)). This is important for conserving 3‑carbon precursors
for glucose synthesis when glucose is scarce. Such long-term adaptive
effect on PDH activity status can partly be explained by altered ex-
pression of PDH kinases (PDKs), which phosphorylate and inhibit the
PDH complex (Holness and Sugden, 2003). There are four PDK iso-
enzymes, PDK1–4, all expressed in a tissue-specific manner (reviewed
in (Jeong et al., 2012)). As suggested by Holness and Sugden, the PDKs
may be considered to act as tissue homeostats supporting adequate
context-dependent regulation of energy fueling pathways (Holness and
Sugden, 2003). In particular, changed PDK4 expression appears to play
an important role in lipid-related metabolic adaptations in various tis-
sues (reviewed in (Holness and Sugden, 2003; Sugden, 2003; Roche and
Hiromasa, 2007)). Increased level of PDK4, e.g. due to starvation (Wu
et al., 2000), favors inactivation of PDH in oxidative tissues, and
thereby implements an influential metabolic shift from glucose to fatty
acid oxidation. Furthermore, under such conditions, reduced produc-
tion of malonyl-CoA, an important inhibitor of mitochondrial fatty acid
uptake and oxidation (the CPT system), will support increased rates of
fatty acid oxidation.
Fatty acid oxidation is also controlled by nutrient- and energy-sen-
sitive factors, such as AMP-dependent protein kinase (AMPK), the fa-
mily of peroxisome proliferator-activated receptor transcription factors
(PPARs) and the mammalian target of rapamycin (mTOR) (recently
reviewed in (Desvergne et al., 2006; Lin and Hardie, 2018; Saxton and
Sabatini, 2017)). The PPAR family consists of three main isoforms
(PPARα, PPARδ, PPARγ), among which PPARα is a central regulator of
context-dependent changes in fatty acid oxidation (Desvergne et al.,
2006). AMPK is activated by a low cellular energy state, which com-
monly leads to increased mitochondrial biogenesis and stimulated
oxidation rates (Hodneland Nilsson et al., 2015; Tronstad et al., 2014).
AMPK also inactivates acetyl-CoA carboxylase (ACC), which is an en-
zyme producing malonyl-CoA (Winder et al., 1997; O'Neill et al., 2014).
Pharmacological activation of AMPK with 5-aminoimidazole-4-car-
boxamide ribonucleotide (AICAR) causes increased fatty acid oxidation
in rat muscle (Merrill et al., 1997). In contrast to PPARα and AMPK, the
activity of mTOR primarily supports biosynthesis rather than catabo-
lism. Hence, in an energy-limited context, e.g. glucose deprivation,
increased rates of mitochondrial fatty acid oxidation may be supported
by multiple regulatory events, including PPARα and/or AMPK activa-
tion, and mTOR inhibition. The contextual effects depend on both the
type of trigger as well as cell-specific properties regarding the con-
tributing signaling factors and their downstream mediators, such as
PDKs. These mechanisms regulate both the activity balance between
glucose and fatty acid oxidation, and the ability to switch between these
fueling pathways, a trait often referred to as metabolic flexibility
(Galgani et al., 2008).
PDK4 is normally highly expressed in tissues with high energy de-
mand, including heart, skeletal muscle, liver, kidney, pancreatic islet
and lactating mammary gland (Holness and Sugden, 2003; Wu et al.,
2000). In these tissues, PDK4 expression is typically induced when the
blood free fatty acid level increases, such as during starvation; and this
is mediated partly through PPARα, but also by other mechanisms
(Jeong et al., 2012; Sugden et al., 2001). PPARα-agonists, such as WY-
14,643, have been found to significantly induce PDK4 expression in rat
muscle (Wu et al., 1999), and PDK4 upregulation through PPARα may
be involved in cancer cachexia (Pin et al., 2019). Further, PDK4 was
reported to be highly upregulated upon cardiac-restricted over-
expression of PPARα in mice, and this was associated with increased
myocardial fatty acid oxidation rates (Finck et al., 2002). Upregulation
of PDK4 was also found in adipocytes after treatment with the PPARγ-
selective activator rosiglitazone, but not liver and muscle (Cadoudal
et al., 2008). In muscle cells, PPARδ was found to mediate contextual
upregulation of PDK4 (Badin et al., 2012; Feng et al., 2014). Although
AMPK and mTOR are known to respond to low energy conditions, there
are few reports on how these factors may affect the relationship be-
tween PDK4 and fatty acid oxidation e.g. upon starvation. Combined
activation of AMPK and PPARδ caused increased Pdk4 expression in
mouse muscle, and this was associated with increased fat oxidation
during prolonged exercise (Manio et al., 2016). The hypolipidemic
modified fatty acid tetradecylthioacetic acid (TTA) is known to act
through multiple mechanisms to induce mitochondrial fatty acid oxi-
dation in cells and animals, both dependent and independent of PPARs
(Berge et al., 2005; Rost et al., 2009; Grav et al., 2003; Wensaas et al.,
2009). Potential effects of TTA on PDK4 expression have not yet been
reported.
Based on current knowledge, increased PDK4 expression appears to
imply a coordinated metabolic shift from glucose to fatty acids as major
energy fuel. The present study was undertaken to solidify the re-
lationship between PDK4 expression and fatty acid oxidation, by pur-
suing in vivo findings through extensive investigations of context-de-
pendent metabolic functions in living cells.
2. Materials and methods
2.1. Rat model
The rat study was part of a larger study previously reported
(Vigerust et al., 2012). The protocol was approved by the Norwegian
State Board of Biological Experiments with Living Animals. Ten weeks
old male Wistar rats (200–250 g) were obtained from Taconic Europe.
After one week of acclimatization, the control group was fed on high fat
diet (23% lard +2% soybean oil), and treatment group was given the
same diet supplemented with TTA (0.375%) for 50 weeks. The diets
were isocaloric (energetic value 4900 Kcal). Animals were anaes-
thetized and sacrificed under non-fasting condition. Blood was drawn
by cardiac puncture. All tissues were stored in liquid nitrogen before
analysis. Further information is provided in (Vigerust et al., 2012).
2.2. Cell culture
All cell cultures were incubated at 37 °C (5% CO2 in air).
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Compounds and materials were from Sigma-Aldrich (St. Louis, MO,
US), and catalogue numbers refers to products from this company,
unless otherwise stated. MDA-MB-231 and HeLa cells were cultured in
DMEM (4.5 g/l glucose, #D5671) supplemented with 10% heat-in-
activated fetal bovine serum (FBS, #SH30079.03, GE Healthcare
Hyclone), 50 μg/ml penicillin/streptomycin (#P-0781) and 2mM L-
glutamine.
2.3. Overexpression of PPARA and PDK4
For the overexpression of PPARA, a double-stranded DNA fragment
(g-Block) encoding human PPARA and containing BamHI and SalI re-
striction enzymes cutting sites was synthesized by Integrated DNA
Technologies (IDT, Coralville, IA, US). The g-block fragment was then
subcloned into the pBABE-puro (Addgene, plasmid 1764) retroviral
vector with a puromycin resistance gene. An empty pBABE-puro vector
was used as a control. HEK293T packaging cells were transfected with
the retroviral vector and packaging vectors by Lipofectamine-2000
transfection (#11668–019, Thermo Fisher Scientific, Waltham, MA,
US), following the manufacturer's instructions. At 5 h post-transfection,
the medium was replaced with 10ml fresh DMEM supplemented with
10% FBS. Virus were harvested after 24 h post-transfection. For retro-
viral infection, MDA-MB-231 cells were seeded in a 10-cm dish and
infected with virus in the presence of polybrene (8 μg/ml). Cells were
selected by puromycin (2 μg/ml) 48 h post infection.
For the overexpression of PDK4, A MMLV retrovirus gene expression
vector containing PDK4 cDNA (NM_002612) and Bsd, the blasticidine
resistance gene (Kimura et al., 1994) was acquired from VectorBuilder
(VectorBuilder Inc. 150 Pine Forest Drive, Suite 803, Shenandoah, TX
77384). HEK293 derived Phoenix-AMPHO (ATCC® CRL-3213™)
packaging cells were transfected with the retroviral vector by Lipo-
fectamine-2000 transfection, following the manufacturer's instructions.
Stably transfected virus producing packaging cells were selected in
DMEM medium containing 10 μg/ml blasticidin (#ant-bl-05, In-
vivoGen, 5, rue Jean Rodier F-31400 Toulouse, France), as described by
others (Pear et al., 1993). For retroviral infection, MDA-MB-231 cells
were seeded in 6-well plates and infected with virus in the presence of
protamine sulfate (5 μg/ml). Cells were selected by blasticidin (10 μg/
ml) 72 h post infection.
2.4. Cell culture treatment conditions
To investigate long-term effects (6 days) of metabolic modulators,
250,000 cells were plated in T75 flasks and incubated overnight to
allow proper attachment. Final concentrations of 5-aminoimidazole-4-
carboxamide 1-β-D-ribofuranoside (AICAR, 0.5 mM, Toronto Research
Chemicals Inc., North York, ON, Canada), rapamycin (50 nM), tetra-
decylthioacetic acid (TTA, 30 μM and 60 μM, Synthetica AS, Oslo,
Norway), 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY
14,643, 10 μM) and vehicle (DMSO, 60 μM) were added to respective
flasks. On day 3, the medium was replaced, and treatment continued.
On day 5, the cells were re-plated at optimized cell densities for sub-
sequent analyses the next day (day 6).
2.5. Extracellular flux analysis to study cell metabolism
Extracellular flux analysis was performed with the Seahorse XFe96
Analyzer (Agilent, Santa Clara, CA, US). This simultaneously measures
the oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) in the medium directly above adherent cells. The experiments
were performed according to standard protocols, and cell number and
compound concentrations were optimized for each cell type. Cells were
seeded in 96-well assay plates (Hela; 20,000, MDA-MB-231; 30,000
cells/80 μl/well) and let adhere overnight (5% CO2 in air, 37 °C). The
next day, growth medium was replaced with assay medium (un-buf-
fered, phenol red-free DMEM, #D5030) supplemented for
mitochondrial respiration assay with 10mM glucose, 2 mM sodium
pyruvate, 4 mM L-glutamine, pH 7.4, and for glycolysis assay with 4mM
glutamine, pH 7.4. After 1 h incubation in the Prep Station (37 °C, CO2-
free, Agilent) the plate was placed in the Seahorse XFe96 Analyzer.
Chemical modulators were injected sequentially to obtain metabolic
flux profiles. For the mitochondrial respiration assay the final con-
centration of the modulators were 3 μM oligomycin, 1 μM CCCP, 1 μM
rotenone and 1 μM antimycin A. For the glycolysis assay, final con-
centrations of 10mM glucose, 3 μM oligomycin and 100mM 2-deox-
yglucose were added.
To study acute effects of palmitic acid (PA) and its modified ana-
logue TTA, the cells (untreated) were seeded according to standard
protocol (described above). The fatty acids (dissolved in DMSO) were
added at specified concentrations (final concentrations: 30, 60, 100 and
200 μM) to the mitochondrial respiration assay medium immediately
before inserting the plate into the Seahorse XFe96 Analyzer.
When relevant, data were normalized to protein content, measured
using the Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific,
Waltham, MA, US).
2.6. Substrate oxidation assay by 14CO2-trapping
Substrate oxidation was assessed by providing the radiolabeled
(14C) substrate of interest to the cells, accompanied by trapping of the
released 14CO2; a technique previously described in (Wensaas et al.,
2007). Cells were seeded in 96-well CellBind® microplates (MDA-MB-
231; 45,000, HeLa; 40,000 cells/well) in DMEM and incubated over-
night to allow proper attachment. The radiolabeled substrate of in-
terest, either [1-14C]pyruvic acid (0.25 μCi/ml), D-[14C(U)]glucose
(2 μCi/ml for MDA-MB-231, 4 μCi/ml for HeLa) or [1-14C]palmitic acid
(1 μCi/ml), all from PerkinElmer (Waltham, MA, US), was given in
DPBS (with MgCl2 and CaCl2, #D8662) supplemented with 10mM
HEPES and 10 μM BSA. L-carnitine (1mM) and glucose (0.5 mM) were
included in the assay medium for palmitic acid oxidation. Respective
amounts of non-radiolabeled substrate were added to obtain final
concentrations of sodium pyruvate (0.2 mM or 2mM), glucose (5mM)
and BSA-conjugated palmitic acid (100 μM), as indicated in the figures.
For uncoupled substrate oxidation, the optimized concentration of
CCCP (1 μM for pyruvate and glucose oxidation, 3 μM for palmitic acid
oxidation) was added to the medium. The optimal CCCP concentration
was higher for palmitic acid oxidation compared to the others due to
the increased amount of BSA, which binds hydrophobic molecules.
Etomoxir (40 μM) was added to selected wells during palmitic acid
oxidation, to monitor the contribution of non-mitochondrial CO2 pro-
duction, which usually was 10–20% of basal activity (data not shown).
The 14CO2 trapping was performed as described (Wensaas et al., 2007).
In brief, an inverted UniFilter®-96w GF/B microplate (PerkinElmer),
activated for CO2 capture with 1M NaOH, was sealed to the top of the
96-well CellBind® cell culture microplate, and incubated for the in-
dicated period of time at 37 °C. Subsequently, scintillation liquid (30 μl,
Ultima Gold XR or MicroScint PS PerkinElmer) was added to the filters
and the filterplate sealed with a TopSealA (PerkinElmer). Radioactivity
was measured using a microplate scintillation counter (TopCount NXT,
Packard, Meriden, CT, US or the MicroBeta2 Microplate Counter, Per-
kinElmer). Protein measurement was performed for data normalization.
The cells were washed twice with PBS, lysed (0.1M NaOH), and mea-
sured using Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific).
2.7. Gene expression by qPCR assays
Gene expression analysis in animal tissues was done as previously
reported (Vigerust et al., 2012; Lindquist et al., 2017; Dyrstad et al.,
2018). RNA was isolated from frozen tissues stored at −80 °C. In cell
culture experiments, the cells were washed with PBS, pelleted and
stored at −80 °C. Cellular RNA was extracted using the RNeasy mini kit
including DNase digestion (RNase-Free DNase) (QIAGEN, Venlo,
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Netherlands). Total RNA (50 ng/μl) was estimated by the use of a Na-
nodrop ND-1000 Spectrophotometer (NanoDrop Technologies, Boston,
MA, US) and reversely transcribed using the Applied Biosystem's High
Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific)
according to manufacturer instructions. All probes were obtained from
Applied Biosystems unless otherwise stated. Probes used were: Acyl-
CoA oxidase 1, (ACOX Human: Hs01074241, Acox Rat: Rn01460628),
Cytochrome c oxidase subunit IV (COX4I1 Human: Hs00971639),
Carnitine palmitoyltransferase 1A (Cpt1a Rat: Rn00580702, CPT1A
Human: Hs00912671), Carnitine palmitoyltransferase 1B (Cpt1b Rat:
Rn00682395), Carnitine palmitoyltransferase 2 (Cpt2 Rat:
Rn00563995), Pyruvate dehydrogenase kinase 4 (Pdk4 Rat:
Rn00585577_m1, PDK4 Human: Hs01037712), Peroxisome proliferator
activated receptor α (PPARA Human: Hs00947536), Malic enzyme-1
(Me-1 Rat: Rn00561502_m1, ME-1 Human: Hs00159110), Mitochon-
drial transcription factor A (Tfam Rat: Rn00580051_m1, TFAM Human:
Hs01082775) and Nuclear respiratory factor (Nrf Rat:
Rn01455960_m1). The reaction mixtures were loaded into a Light-
Cycler® 480 Multiwell Plate 384 (Roche, Basel, Germany) by the Mos-
quito HV® low volume pipetting instrument (TTP Labtech Ltd., UK)
(Dyrstad et al., 2018). The qPCR was run in a LightCycler 480 system
(Roche, Basel, Germany) with the “Dual Color Hydrolysis probe – UPL
Probe 384-11” instrument template-program. The expression level of
each gene was calculated as fold change based on the delta delta Ct
method (Livak and Schmittgen, 2001) and was normalized against 18S
rRNA (Rat: RT-CKFT-18S from Eurogentec, Seraing, Belgium, Human:
Eukaryotic 18S rRNA Endogenous Control, 4310893E).
2.8. Protein expression by western blotting
The cell pellets were lysed in RIPA lysis buffer (#sc24948, Santa
Cruz Biotechnology, Dallas, TX) following the manufactures instruc-
tions. Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific) was
used to measure protein concentration in the lysates. The protein lysate
mixed together with XT Sample Buffer (#1610791, Bio-Rad) were he-
ated at 95 °C for 5min, before 10–12mg protein was loaded per well.
The electrophoresis was done using Mini-PROTEAN® TGX™ Protein
Gels, 4–20% gradient, running buffer (#1610772, Bio-Rad) and Bio-
Rad Mini Protean 3 cell system (90 V for 15min, 110 V for 1 h). The
BioradTurbo Transfer System (2.5A, 25 V, 7min) was used to transfer
(transfer buffer, #1610734, Bio-Rad) the proteins onto the activated
(30 s in metanol) polyvinylidene fluoride (PVDF) membrane (Trans-
Blot® Turbo™Mini-size LF PVDF). The membranes were blocked, for 1 h
in room temperature, in Odyssey Blocking Buffer (TBS) (LI-COR
Biosciences) before labeled with anti-PDK4 antibody (#ab11033,
mouse monoclonal [1C2BG5], Abcam) diluted 1:500 in blocking buffer
overnight at 4 °C. Anti-GAPDH antibody (#60004–1, mouse mono-
clonal, Proteintech) at a dilution of 1:1000 was used as loading control.
After washing in TBS-T buffer the membranes were incubated for 2 h in
IRDye® 800CW Goat anti-Mouse IgG secondary antibody (1:20000)
(#P/N 926–32,210, LI-COR Bioscience). The protein bands were vi-
sualized using the 800 nm IRlong channel in the Amersham Typhoon
Gel and Blot Imaging Systems (GE healthcare). Amersham™ Imager 600
software was used to view and analyze the blot images together with
ImageJ software.
2.9. Live-cell reporter strategy to monitor mitochondrial biogenesis
Mitochondrial biogenesis was measured using a GFP-based live-cell
reporter strategy previously described in (Hodneland Nilsson et al.,
2015). Briefly, a reporter construct (NRF1mitoGFP) with mitoGFP
under the control of a promoter with NRF-1 responsive element was
inserted into HeLa (HeLaNRF1/c4) and MDA-MB-231 (MDA-MB-231/
NRF1) cells. Following the treatment, the cellular expression of mi-
toGFP (fluorescence intensity) was measured as a readout of mi-
tochondrial biogenesis. The cells were treated as indicated for 6 days,
before they were trypsinized, washed with PBS and kept on ice until
analyzed by flow cytometry (AccuriTM C6, BD Accuri Cytometers Inc.,
Ann Arbor, MI, US). The data were analyzed by FlowJo software.
2.10. Plasma lactate and glucose measurements
Biosen C-Line GP+ (EKF Diagnostics, Cardiff, UK) was used to
measure glucose and lactate concentrations in rat plasma, according to
manufacturer's instructions.
2.11. Statistical analysis
All data were analyzed using Graphpad Prism 8 software (Graph-
Pad Software; San Diego, CA, US). Results are shown as mean ± SD.
ANOVA and student's t-test were used to evaluate statistical differences
between the interventions and control. Pearson's correlation coeffi-
cients were used when comparing two independent variables. P < .05
was considered statistically significant.
3. Results
3.1. Pdk4 expression is a sensitive indicator of mitochondrial fatty acid
oxidation in rat tissues
Increased hepatic fatty acid oxidation is established as an important
mechanism behind the hypolipidemic effects of the modified fatty acid
TTA in rats (Berge et al., 2005). In multiple studies, upregulated fatty
acid oxidation has been demonstrated, both based on gene expression
and enzymatic activity, most extensively in liver, but also in heart
(Berge et al., 2005; Vigerust et al., 2012; Oie et al., 2013; Turell, 1989).
In the present study, we used TTA-treatment as a model to evaluate the
relationship between Pdk4 mRNA expression and fatty acid oxidation in
vivo. Gene expression was measured in tissue samples from a previous
experiment in rats, where rats were treated with TTA for 50 weeks
(Vigerust et al., 2012). Pdk4 expression was compared with the ex-
pression of genes related to fatty acid oxidation in liver, heart, skeletal
muscle and white adipose tissue (Fig. 1A, and Supplementary Fig. S1).
In the liver of TTA-treated rats, the level of Pdk4 mRNA increased 18-
fold (18.0 ± 2.6), compared to control rats. This was associated with
increased hepatic expression of Cpt1a (liver isoform, 2.4 ± 0.8), Cpt2
(5.1 ± 1.2), and the classical PPARα target gene Acox (10.1 ± 2.8),
supporting previous findings (Vigerust et al., 2012). Interestingly, TTA-
treatment caused a potent increase in the expression of the muscle
isoform Cpt1b in liver (487.1 ± 195.4), which has not previously been
reported. The hepatic expression of Tfam was increased (2.4 ± 1.1)
suggesting that elements of mitochondrial biogenesis may be involved,
although Nrf1 was not affected. We also analyzed the expression of
cytosolic malic enzyme Me-1 due to its interactions in pyruvate meta-
bolism, as well as fatty acid oxidation by mediating TCA anaplerotism
(Gibala et al., 2000; Carley et al., 2015). TTA-treated rats presented
significantly increased expression of Me-1 in liver (58.0 ± 21.9). In
heart, a moderate induction of Pdk4 (2.5 ± 0.7) was accompanied by
relatively small, but statistically significant, increases in Cpt1b
(1.2 ± 0.1), Acox (1.7 ± 0.3) andMe-1 (1.5 ± 0.3) mRNA levels, and
a small reduction in Tfam (0.8 ± 0.04), whereas the other transcripts
remained unchanged. None of these genes were significantly affected in
skeletal muscle or white adipose tissue in TTA-treated rats compared to
controls. Plasma glucose and lactate levels were measured to evaluate
how this long-term adaptation of oxidative metabolism affected sys-
temic glucose homeostasis (Fig. 1B-C). While no effect was found for
plasma lactate, the plasma glucose levels tended to be slightly lower in
TTA-treated rats compared to controls, although this effect did not
reach statistical significance. In summary, TTA-treated rats presented
regulatory effects on fatty acid oxidation genes in agreement with a
significant induction in liver and a moderate induction in heart, sup-
porting previous measurements (Berge et al., 2005; Oie et al., 2013).
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Importantly, upregulation of fatty acid oxidation was accompanied by
increased Pdk4 expression, generally to a higher magnitude compared
to other genes commonly used as indicators of mitochondrial fatty acid
oxidation.
3.2. Fatty acid oxidation and PDK4 expression are strongly induced by
PPARA-overexpression
As a proof of principle cell model where upregulation of fatty acid
oxidation is expected, we investigated PDK4 mRNA expression in MDA-
MB-231 cells modified to overexpress PPARA (MDA-MB-231/PPARA,
Fig. 2). Based on our previous experience with various cell models, the
MDA-MB-231 line was chosen as the primary model due to its active
oxidative metabolism, and the observation that these cells present a
significant increase in fatty acid oxidation under relevant conditions.
Several of the experiments were also repeated with HeLa cells, which
we commonly find to display similar metabolic effects as MDA-MB-231,
albeit often less pronounced.
The mRNA level of PPARA was 82.3 ± 14.4-fold higher in the
MDA-MB-231/PPARA cells, compared to the parental cells.
Noteworthy, this caused a 24.9 ± 1.8-fold increase in PDK4 mRNA
level, and upregulation of genes involved in fatty acid catabolism such
as ACOX (51.0 ± 12.5), CPT1A (2.3 ± 0.1), COX4I1 (1.9 ± 0.05)
and ME-1 (2.0 ± 0.03) (Fig. 2A). The expression of the mitochondrial
transcription factor TFAM was slightly reduced (0.7 ± 0.04) in the
MDA-MB-231/PPARA cells, suggesting that the increased expression of
these mitochondrial enzymes was not linked to increased mitochondrial
biogenesis.
To investigate if PPARA overexpression caused a metabolic fuel
change, we measured glucose and fatty acid oxidation by trapping
14CO2 produced under incubation with the respective radiolabeled
substrates. Fatty acid oxidation was increased nearly three-fold in the
MDA-MB-231/PPARA cells compared to the parental cells (Fig. 2B). In
the same cells, glucose oxidation was reduced by 20%, when glucose
was provided as the major substrate (Fig. 2C). These data support the
notion that PDK4 expression and fatty acid oxidation are co-regulated
by PPARα, leading to an overall metabolic shift towards increased
oxidation of fatty acid instead of glucose.
3.3. PDK4 overexpression leads to increased fatty acid oxidation
The increase in PDK4 expression may occur as a parallel effect be-
sides the stimulated fatty acid oxidation, or it may be a causative factor
of the metabolic shift. To address this question, we investigated the
effects of PDK4 overexpression in MDA-MB-231 cells (i.e. MDA-MB-
231/PDK4 cells). The levels of PDK4 mRNA and protein were low in the
parental cells, and the increased amounts in the modified cells con-
firmed successful overexpression (Fig. 3A-B). Although the PDK4 anti-
body gave weak band intensity, the immunoblot showed increased level
in PDK4-overexpressing cells (Fig. 3B). We then investigated if this
leads to reduced pyruvate oxidation, which would be the expected
consequence of PDK4-mediated inhibition of the PDH complex. Fol-
lowing incubation in high glucose environment (25mM), pyruvate
oxidation was 32% reduced in the MDA-MB-231/PDK4 cells (borderline
statistical significance), compared to the parental cells (Fig. 3C). This
activity was stimulated in both cell types when grown in low glucose
compared to high glucose medium, but pyruvate oxidation remained
lower in the MDA-MB-231/PDK4 compared to the parental cells. No-
teworthy, fatty acid oxidation was 74% increased in PDK4 over-
expressing cells compared to parental cells when grown in 25mM
glucose, but the difference disappeared following growth in 1mM
glucose, primarily due to a significant increase in the parental cells
(Fig. 3D). These data strongly support that there is a tight causative
relationship between PDK4 and fatty acid oxidation. Apparently, PDK4
overexpression lead to a shift towards fasting-type energy metabolism
even in a high glucose environment. Hence, the differences between
parental and PDK4 overexpressing cells were smaller following growth
in a low glucose environment, since this significantly enhanced fatty
acid oxidation in the parental cells but not to the same extent in PDK4-
overexpressing cells.
Fig. 1. Pdk4 expression and metabolic adaptation in TTA-treated rats.
Rats were administered control (CTR) or TTA-supplemented diet for 50weeks (Vigerust et al., 2012). (A) Gene expression in liver, heart, skeletal muscle and white
adipose tissue (WAT) was measured using real time quantitative PCR. The heat map indicates mean expression level relative to control (ddCT method, detailed data
in Supplementary Fig. S1). (B) Glucose and (C) lactate concentrations in plasma from the CTR and TTA fed rats. Each dot represent one animal and group mean ± SD
(n=8–10) is indicated. Statistical analysis was performed by t-test. *p < .05, p-values are shown in (B) and (C). TTA, tetradecylthioacetic acid.
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3.4. Increased PDK4 expression reflects upregulated fatty acid oxidation
under conditions of metabolic adaptation
In order to investigate the relationship between fatty acid oxidation
and PDK4 expression in different contexts of metabolic adaptation, we
studied the effects of long-term (6 days) treatment with TTA and se-
lective activators of AMPK (AICAR) and PPARα (WY 14,643) in MDA-
MB-231 cells. The mRNA level of CPT1A, which often is used as an
indicator of mitochondrial fatty acid oxidation, was lower after treat-
ments with AICAR and WY 14,643, compared to control, but increased
approximately two-fold in cultures treated with 30 μM or 60 μM TTA
(Fig. 4A). The effect of TTA on PDK4 expression was of significantly
higher magnitude (7.3 ± 0.3 at 30 μM TTA, 12.2 ± 1.2 at 60 μM TTA)
compared to CPT1A. AICAR treatment caused reduced PDK4 expres-
sion, whereas WY 14,643 had no effect. None of the agents were found
to induce the mRNA expression of the classical PPARα-target ACOX in
these cells. Only AICAR induced the expression of TFAM (2.7 ± 0.1),
suggesting that this treatment, in contrast to the others, causes activa-
tion of mitochondrial biogenesis. Replication of this experiment with
Hela cells supported that TTA, but not AICAR and WY 14,643, caused
moderate upregulation of CPT1A simultaneous with a strong induction
of PDK4 (Supplementary Fig. S2). HeLa cells tended to have a mild
upregulation of TFAM and ACOX expression for all the treatments ex-
cept for 60 μM TTA.
The highest concentration of TTA (60 μM) caused a 4-fold increase
in basal fatty acid oxidation in MDA-MB-231 cells, and the effect was
slightly less with the lower concentration (30 μM) (Fig. 4B). In our
experience, functional changes of this magnitude in cell metabolism are
rarely observed in living cell cultures. AICAR and WY 14,643 did not
affect fatty acid oxidation in these cells. Additional measurements in
presence of the mitochondrial uncoupler carbonyl cyanide 3-chlor-
ophenylhydrazone (CCCP) showed that the maximal fatty acid oxida-
tion capacity was approximately two-fold increased in the TTA-treated
cells (for both TTA concentrations). Enhanced fatty acid oxidation in
TTA-treated cells was not found to be accompanied by a reciprocal
reduction in basal glucose oxidation, yet there was a moderate decrease
in AICAR-treated cells (Fig. 4C). We then measured pyruvate oxidation
in order to obtain a more direct assessment of mitochondrial oxidation,
disconnected from the potential rate-limiting influence of glycolysis.
Basal pyruvate oxidation tended to be reduced after treatment with
60 μM TTA, with as significant 30% reduction under uncoupling con-
ditions (Fig. 4D). Similar effects were seen in HeLa cells after treatment
with AICAR, WY 14,643 or TTA (Supplementary Fig. S2). In summary,
metabolic adaptation involving induced fatty acid oxidation was ac-
companied by strongly increased PDK4 mRNA expression in these cell
models. This effect was observed after treatment with TTA known to
regulate multiple energy-sensitive mechanisms, but not with selective
activators of AMPK (AICAR) or PPARα (WY 14,643), under these
Fig. 2. Effect of PPARA overexpression on PDK4 expression and fuel oxidation.
The effects of increased PPARA expression were investigated in MDA-MB-231 cells. The figure compares the unmodified (231 Parental) and PPARA overexpressing
(231 PPARA) cells. (A) Expression of PPARA, PDK4, CPT1A, ACOX, TFAM, COX4I1 and ME-1, measured using real time quantitative PCR. The diagrams show mRNA
expression relative to the CTR group (ddCT method), as mean ± SD of triplicate measurements. (B) Fatty acid oxidation; 14CO2-production during 4 h incubation
with [1-14C]palmitic acid (1 μCi/ml, 100 μM), in presence of L-carnitine (1mM) and glucose (0.5mM). (C) Glucose oxidation; 14CO2-production during 4 h incubation
with D-[14C(U)]glucose (2 μCi/ml, 5 mM). The oxidation data are normalized to cell protein content (mg), and are displayed as mean ± SD of 4–8 replicates. The
pathway illustrations show the carbon flux fueled by the 14C-labeled substrates. The filled and open circles represent radiolabeled (filled, 14C) and non-labeled (open)
carbons, released as CO2 under the respective conditions. The shown experiments are representative for three separate experiments. Statistical analysis was per-
formed by t-test. *p < .05, **p < .01, ***p < .001, ****p < .0001.
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experimental conditions.
A previously established genetic reporter strategy was utilized to
further evaluate the potential role of mitochondrial biogenesis under
these conditions (Hodneland Nilsson et al., 2015). The reporter con-
struct consists of a gene for mitochondrial GFP under the control of a
responsive element of NRF1, which is a central nuclear transcription
factor controlling expression of mitochondrial proteins. Single cell
analysis was performed by flow cytometry in HeLa and MDA-MB-231
cells containing the reporter construct, following treatments with
AICAR, WY 14,643 or TTA (Fig. 4E). Only AICAR was found to have a
significant effect on mitochondrial biogenesis in HeLa cells, and this
agreed with the findings in MDA-MB-231 cells (borderline statistical
significance). This effect of AICAR was also previously observed in HeLa
cells (Hodneland Nilsson et al., 2015). Both the genetic reporter results
and the TFAM expression data indicated that the fuel shift from glucose
to fatty acids occurs without simultaneous induction of mitochondrial
biogenesis in these cell types. Western blot analysis supported that
PDK4 protein abundance was increased following treatment with TTA,
but not WY 14,643, in HeLa cells (Fig. 4F).
3.5. Effects of metabolic adaptation on mitochondrial respiration and
glycolysis
To investigate if increased fatty acid oxidation was associated with
changes in mitochondrial respiration, we measured oxygen consump-
tion rate (OCR) in MDA-MB-231 cells after long-term (6 days) treatment
with AICAR, WY 14,643 or TTA, and upon overexpression of PPARA
(Fig. 5). Following measurement of the basal respiratory rate, we as-
sessed descriptors of mitochondrial function through sequential addi-
tions of pharmacological modulators. Leak respiration rate was ob-
tained after addition of oligomycin (ATP synthase inhibitor), and
subsequently CCCP was administered to measure uncoupled respiratory
capacity. Rotenone (respiratory complex I inhibitor) was then added,
followed by antimycin A (respiratory complex III inhibitor) to assess
non-mitochondrial activity (residual oxygen consumption, background
activity). Interestingly, the basal respiratory rates were similar among
the different conditions of metabolic adaptation (AICAR, WY 14,643,
TTA and PPARA overexpression), and compared to respective controls
(untreated and DMSO (vehicle)), with a minor increase in cultures
treated with WY 14,643 and 60 μM TTA. Leak respiration was increased
2–3-fold in the TTA treated cultures compared to control (DMSO),
Fig. 3. Effect of PDK4 overexpression in pyruvate and fatty acid oxidation.
The effects of PDK4 overexpression were investigated in MDA-MB-231 cells. The figure compares the unmodified (231 Parental) and PDK4 overexpressing (231
PDK4) cells. (A) Confirming overexpression of PDK4 using real time quantitative PCR. The mRNA expression level is displayed relative to the 231 Parental cells (ddCT
method) as mean ± SD of triplicate measurements, and is representative for two separate experiments. (B) Increased PDK4 protein expression was confirmed by
Western blot analysis. (C-D) Pyruvate and fatty acid (palmitic acid) oxidation was measured following overnight pre-incubation in medium with 1mM or 25mM
glucose. (C) Pyruvate oxidation; 14CO2-production during 4 h incubation with [1-14C]pyruvic acid (0.25 μCi/ml, 0.2 mM), in presence of glucose (0.5 mM). (D) Fatty
acid oxidation; with [1-14C]palmitic acid (1 μCi/ml, 100 μM), in presence of L-carnitine (1mM) and glucose (0.5mM). The oxidation data are normalized to cell
protein content (mg) and are displayed as mean ± SD of 4–8 replicates, from one representative of three separate experiments. The pathway illustrations show
carbon flux fueled by the 14C-labeled substrates. The filled and open circles represent radiolabeled (filled, 14C) and non-labeled (open) carbons released as CO2 under
the respective conditions. Statistical analysis was performed by t-test. *p < .05, **p < .01, ***p < .001, ****p < .0001.
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Fig. 4. PDK4 expression and fatty acid oxidation in contexts of metabolic adaptation.
MDA-MB-231 were treated for 6 days with AICAR (0.5mM), WY 14,643 (10 μM) or TTA (30 μM or 60 μM). Control cultures were untreated (UNTR, for AICAR) or
DMSO-treated (DMSO, for WY 14,643 and TTA). (A) Real time quantitative PCR analysis of TFAM, ACOX, CPT1A and PDK4. The diagrams show mRNA expression
relative to the control group (ddCT method), as mean ± SD of triplicate measurements. (B-D) Substrate oxidation was assessed by measuring 14CO2-production
during 4 h incubation with the respective radiolabeled substrate, in the absence and presence of an uncoupler (CCCP). (B) Fatty acid oxidation; with [1-14C]palmitic
acid (1 μCi/ml, 100 μM), in presence of L-carnitine (1mM) and glucose (0.5 mM). (C) Glucose oxidation; with D-[14C(U)]glucose (2 μCi/ml, 5 mM). (D) Pyruvate
oxidation; with [1-14C]pyruvic acid (0.25 μCi/ml, 2 mM). CCCP concentrations were 1 μM for glucose and pyruvate oxidation, and 3 μM for palmitic acid oxidation
(higher due to the increased BSA concentration). The oxidation data are normalized to cell protein content (mg) and shown as mean ± SD of 4–8 replicates. The
pathway illustrations show the carbon flux fueled by the 14C-labeled substrates. The filled and open circles represent radiolabeled (filled, 14C) and non-labeled (open)
carbons, released as CO2 under the respective conditions. (E) Measurement of mitochondrial biogenesis using a GFP-based reporter construct in HeLa and MDA-MB-
231 cells. The reporter cells were treated before mitoGFP was detected by flow cytometry (10,000 cells per sample). (F) Western blot analysis of PDK4 in HeLa cells
treated for 6 days with TTA (30 μM or 60 μM) or WY 14,643 (10 μM). All diagrams display representative data as, mean ± SD, for three separate experiments.
Statistical analysis was performed by t-test. *p < .05, **p < .01, ***p < .001, ****p < .0001.
Fig. 5. Analysis of mitochondrial respiration and glycolysis.
Oxygen consumption rate (OCR) and extracellular acidification rates (ECAR) were measured in MDA-MB-231 cells after 6 days treatment with AICAR (0.5mM), WY
14,643 (10 μM) and TTA (30 μM or 60 μM), and in cells overexpressing PPARA. Control cultures were untreated (UNTR, for AICAR and PPARA) or DMSO-treated
(DMSO, for WY 14,643 and TTA) cells. (A) Representative traces of OCR (pmol O2/min/μg protein). Following measurement of basal respiration (BASAL), specific
modulators were added as indicated: 3 μM oligomycin to obtain leak respiration (LEAK), 1 μM CCCP to access uncoupled respiration (UNC), 1 μM rotenone to
measure rotenone-resistant respiration (ROT) and 1 μM antimycin A to measure residual oxygen consumption (ROX). (B) Data extracted from the analyses in A, after
subtraction of non-mitochondrial activity (ROX). (C) Analysis of functional integrity of mitochondria. Rates of interest calculated as % of basal OCR. (D)
Representative traces of ECAR (mpH/min/μg protein). The specific modulators were added following measurement of endogenous activity (ENDOG), as indicated:
10mM glucose (GLC) to obtain basal glycolysis (BASAL), 3 μM oligomycin to assess glycolytic capacity (CAP) and 100mM 2-deoxyglucose (2DG) to measure non-
glycolytic activity (non-Glyc). (E) Data extracted from the analyses in D. (F) Analysis of glycolytic function. Rates of interest calculated as % of basal ECAR. Data are
displayed as mean ± SD of 6–8 replicates, from one representative of three separate experiments Statistical analysis was performed by ANOVA. *p < .05,
**p < .01, ***p < .001, ****p < .0001.
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apparently in a concentration-dependent manner. The uncoupled re-
spiratory capacity was not significantly affected by AICAR, TTA or
PPARA-overexpression, however, WY 14,643 caused approximately
20% increase compared to the control (DMSO) (Fig. 5B). Calculating
these data as percentage of the basal respiratory rate (Fig. 5C) revealed
that TTA significantly increased the fraction of oxygen consumption
associated with leak respiration, and therefore caused a congruent de-
crease in ATP-linked respiration. The effects of the treatments on the
relative respiratory capacity (uncoupled) were generally negligible,
while TTA significantly reduced the reserve capacity. The findings were
reproduced in HeLa cells (Supplementary Fig. S3). In summary, the
highly increased fatty acid oxidation rate observed after treatment with
TTA and upon overexpression of PPARA was not associated with major
changes in basal mitochondrial respiration. However, TTA led to effects
consistent with mild uncoupling, which may represent an additional
mechanism contributing to metabolic adaptations.
Analysis of glycolytic function was performed by monitoring ex-
tracellular acidification rate (ECAR) following sequential additions of
glucose to obtain basal respiratory rate, oligomycin to measure glyco-
lytic capacity, and 2-deoxyglucose to determine non-glycolytic activity
(Fig. 5D). There was a general reduction in normalized ECAR after
treatment with AICAR and WY 14,643 in MDA-MB-231 cells (Fig. 5E),
but upon additions of glucose and upon addition of oligomycin, the
relative rates were similar to control (Fig. 5F), suggesting that glyco-
lysis was modulated as normal under these conditions. No change in
glycolytic activity was found in PPARA-overexpressing cells, compared
to control cells. TTA-treated cells were also similar to control, but had a
relatively high non-glycolytic acidifying component, displayed both
before addition of glucose and after addition of 2-deoxyglucose. The
TTA-treated cells tended to have slightly reduced reserve glycolytic
capacity, and this was statistically significant in the cultures treated
with 60 μM TTA (Fig. 5F). Similar findings were obtained in HeLa cell
cultures, where TTA also caused a statistically significant increase in
normalized basal glycolysis (Supplementary Fig. S3). In summary, the
effects of metabolic modulators on glycolysis did not demonstrate a
strong correlation with the changes in fatty acid oxidation under these
conditions.
3.6. Mild uncoupling may contribute to increased fatty acid oxidation upon
TTA-treatment
Based on the obtained data suggesting an uncoupling effect of TTA
on mitochondrial respiration, we designed an experiment to investigate
if TTA may mediate such effects through an acute mechanism. TTA was
compared with palmitic acid, a normal saturated fatty acid, when
added at different concentrations to MDA-MB-231 cells immediately
before OCR analysis (Fig. 6A-B). Acute uncoupling activity could then
be detected as an increase in leak respiration after addition of oligo-
mycin. The data clearly demonstrated that TTA, but not palmitic acid,
caused a concentration-dependent increase in leak respiration (Fig. 6C).
Both TTA and palmitic acid caused a minor concentration-dependent
decrease in uncoupled respiration after addition of CCCP (Fig. 6D). The
uncoupling property of TTA was found to be relatively mild, as the
highest concentration of 200 μM, which exceeds the normally tolerable
concentration for cell survival, caused approximately 30% uncoupling
compared to full uncoupling mediated by 1 μM CCCP (Fig. 6E). These
findings were also reproduced in HeLa cells (Supplementary Fig. S4).
Our data suggest mild uncoupling as a new mechanism of TTA, which
induces an additional energy stress likely to influence and accentuate
effects on nutrient-sensitive fueling pathways to support energy
homeostasis. Such a mechanism may explain the effects related to the
changed energy state previously observed in rat liver (Grav et al.,
2003).
3.7. PDK4 expression reports synergistic effects of TTA and rapamycin on
fatty acid oxidation
Rapamycin, an inhibitor of mTOR, has previously been found to
increase fatty acid oxidation (Sipula et al., 2006). Further, studies in rat
hepatocytes have linked the effects of TTA to regulation of mTOR
(Hagland et al., 2013). To investigate if mTOR inhibition influences
TTA-mediated metabolic adaptation, we treated MDA-MB-231 with
TTA and rapamycin, separately and in combination. Rapamycin alone
did not affect mRNA expression of CPT1A and PDK4. In combination
with TTA, however, the levels of both these mRNAs were significantly
higher than in cells treated with TTA alone (Fig. 7A-B). Exactly the
same pattern was seen on rates of fatty acid oxidation, both under basal
and uncoupled conditions (CCCP) (Fig. 7C). Further, we performed
correlation analysis of PDK4 and CPT1A expression relative to fatty acid
oxidation, with data from different conditions of metabolic adaptation
(Fig. 7D). Expression of PDK4 and CPT1A was found to correlate
strongly with each other, and with fatty acid oxidation activity. These
data support a tight regulatory and functional relationship between
PDK4 expression and fatty acid oxidation in different metabolic con-
texts. An advantage of using PDK4, above CPT1A, as an indicator of
fatty acid oxidation would be the significantly higher magnitude of
induction, and therefore a larger dynamic range and higher sensitivity.
4. Discussion
This study shows that upregulated PDK4 mRNA expression is
strongly associated with increased activity of mitochondrial fatty acid
oxidation in metabolically adapted cells and rat tissues. Overall, we
found good correlation between the relative magnitude of PDK4 upre-
gulation and the accompanying increase in fatty acid oxidation. Based
on these findings, we suggest that PDK4 mRNA expression may be used
as a sensitive surrogate marker for changes in mitochondrial fatty acid
oxidation when investigating (pato)physiological adaptations of energy
metabolism.
The activity of mitochondrial fatty acid oxidation is influenced by
many factors, including diet, physical activity, toxic exposure, epige-
netics and mutations. An unhealthy impact on fatty acid oxidation
could lead to suboptimal energy balance, energy deficiency, excessive
lipid storage and metabolic stresses, which ultimately contribute to
pathogenesis both at an organ and systemic level (Adeva-Andany et al.,
2018). On the other hand, metabolic adaptations may have positive
impact, for instance in response to endurance training which increases
the capacity of mitochondrial fatty acid oxidation to accommodate the
elevated demands of energy (ATP) (Booth et al., 2015). In the labora-
tory, mitochondrial fatty acid oxidation may be assessed by measuring
the products formed when radiolabeled fatty acid substrates are pro-
vided to intact cells or fresh preparations (extracts, homogenates) of
cell cultures or tissues (e.g. (Wensaas et al., 2007)). However, such
methods are often inaccessible, or incompatible with regards to the
available sample material. Measurement of surrogate markers, such as
mRNA expression of relevant genes, may therefore represent an at-
tractive strategy to study regulatory effects on fatty acid oxidation. As
far as we know, there is no consensus to which gene targets that are
optimal for serving as expression reporters of a metabolic shift invol-
ving increase in fatty acid oxidation. As for enzymes of the fatty acid
oxidation machinery, the changes in mRNA expression are often found
subtle and with complex cell-type specific regulation. Therefore, we
investigated PDK4 expression as a possible candidate for such purpose,
under conditions of metabolic adaptation driven by different regulatory
programs involving AMPK, PPARs and mTOR, which are relevant for
mechanisms of exercise, starving, obesity and contexts of defective
metabolism.
In rats that were treated with TTA for 50 weeks, we found sig-
nificantly increased expression of Pdk4 particularly in liver, and to
some extent in heart, but not in skeletal muscle and white adipose tissue
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(WAT). This parallels well with increased rates of mitochondrial fatty
acid oxidation especially in liver, and also in heart tissue, of TTA-
treated rats (Berge et al., 2005; Oie et al., 2013). In addition, we found a
pronounced increase in the muscle isoform Cpt1b in liver, yet only a
minor increase in heart, and no detectable effect in muscle and WAT.
TTA also caused significantly increased Me-1 expression in rat liver,
supporting that strengthened TCA anaplerotism contributes to the
adaptation of high mitochondrial fatty acid oxidation rates (Gibala
et al., 2000; Carley et al., 2015). These data underscore the importance
of context- and tissue-specific influences on gene regulation associated
with the fatty acid oxidation machinery. Interestingly, PDK4 upregu-
lation was consistently presented under conditions of increased fatty
acid oxidation in our studies, both in vivo and in vitro.
In cultured MDA-MB-231 cells, we found highly increased PDK4
expression accompanying enhanced mitochondrial fatty acid oxidation
upon PPARA-overexpression and after long-term treatment with TTA.
Congruently, PDK4-overexpression caused reduced pyruvate oxidation
simultaneously with increased fatty acid oxidation when the cells were
grown in high glucose. When transferred to low glucose conditions,
fatty acid oxidation in the parental cells increased to the same level as
the PDK4-overexpressing cells. This supports the theory that increased
PDK4 expression contributes to fasting/starving-type metabolism with
stimulated fatty acid oxidation (Wu et al., 2000), and our findings
suggest that this program is constitutively active in the PDK4–overex-
pressing cells. Hence, there is strong evidence for a tight regulatory and
functional relationship between PDK4 and the fatty acid oxidation
pathway. Direct activation of PPARα with WY-14,643 had no effect on
fatty acid oxidation in MDA-MB-231 cells, possibly due to a low en-
dogenous amount of this transcription factor, since overexpression
caused classical effects on cellular gene expression and metabolism. The
AMPK activator AICAR induced TFAM expression, suggestive of in-
creased mitochondrial biogenesis as previously observed in HeLa cells
(Hodneland Nilsson et al., 2015); however, there was no effect on mi-
tochondrial fatty acid oxidation. On the contrary, AICAR had a sup-
pressive effect on CPT1A and PDK4 expression. This is compatible with
previous findings in rat adipose tissue (Wan et al., 2010), but not in
skeletal muscle (Merrill et al., 1997). Interestingly, in addition to the
known function as panPPAR activator, TTA was found to act directly as
a mild mitochondrial uncoupler, which may contribute to the changed
energy state previously observed in rat liver (Grav et al., 2003). In that
study, reduced mitochondrial membrane potential was found in rat
liver after treatment with TTA, however, it remained unclear if this
could be a direct or indirect mechanism. Due to the acute effects in our
present cell culture study, it seems likely that TTA has a direct un-
coupling effect on the mitochondrial inner membrane.
Inhibition of mTOR by rapamycin did not induce fatty acid oxida-
tion or PDK4 expression in MDA-MB-231 cells, but it accentuated the
effects of TTA, suggesting that mTOR can act together with other
pathways of metabolic adaptation in a context-dependent manner. In
support, mTOR has been found to be regulated by the level of PDK4 in
Fig. 6. TTA exerts mild uncoupling activity.
Oxygen consumption rate (OCR) was measured in MDA-MB-231 cells immediately after administration palmitic acid (PA) or tetradecylthioacetic acid (TTA), at
concentrations of 30–200 μM. (A-B) Representative traces of OCR as % of initial rate (BASAL), in presence of PA or TTA. Specific modulators were added as indicated:
3 μM oligomycin to obtain leak respiration (LEAK), 1 μM CCCP to access uncoupled respiration (UNC), 1 μM rotenone to measure rotenone-resistant respiration
(ROT) and 1 μM antimycin A to measure residual oxygen consumption (ROX). (C) LEAK respiration and (D) UNCOUPLED respiration shown as % of basal OCR. (E)
Uncoupling activity mediated by PA and TTA, compared to complete uncoupler, CCCP (100%). The agent-induced LEAK rate (i.e. LEAKX - LEAKCTR) was calculated
relative to the CCCP-induced LEAK rate (i.e. UNCCCCP-LEAKCTR). Data are displayed as mean ± SD of 6–8 replicates, from one representative of three separate
experiments. Statistical analysis was performed by ANOVA. *p < .05, **p < .01, ***p < .001, ****p < .0001.
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cultured cells (Liu et al., 2014). In separate experiments, we found the
effects in HeLa cells to be similar to the observations in MDA-MB-231
cells.
A rather striking observation was the minor changes regarding mi-
tochondrial respiration and lactate production under basal cell culture
assay conditions, despite the pronounced changes in metabolic fuel
utilization indicated by increased fatty acid oxidation. This suggests
that the increase in fatty acid oxidation did not change the activity
balance between mitochondrial respiration and glycolysis, but rather a
change in substrate preference serving to maintain the supply of acetyl-
CoA for the TCA cycle. This type of cellular metabolic adaptation is
likely to affect properties of metabolic flexibility and associated stress
mechanisms, and therefore the susceptibility for changes in nutrient
supply. The present study primarily investigated metabolic effects
under standard cell culture conditions, which includes high glucose
concentration (normally 25mM in DMEM), and favorable effects on
glycolysis are expected to occur under such conditions. The dependency
on mitochondrial oxidative metabolism following relevant adaptations
of fuel utilization may be addressed further e.g. by reducing the amount
of glucose, or replacing glucose with galactose in the culture medium
(Arroyo et al., 2016).
Systemic and cellular nutrient-sensitive mechanisms in the body
Fig. 7. Synergistic effects of TTA and rapamycin on fatty acid oxidation.
MDA-MB-231 were treated for 6 days with TTA (30 μM) or rapamycin (50 nM, RAP), separately and in combination. (A) CPT1A and (B) PDK4 expression was
measured using real time quantitative PCR as mean ± SD of triplicate measurements. (C) Fatty acid oxidation was assessed by measuring 14CO2-production during
4 h incubation with [1-14C]palmitic acid (1 μCi/ml, 100 μM) in presence of L-carnitine (1mM) and glucose (0.5 mM), with and without an uncoupler (3 μM CCCP).
The oxidation data are normalized to cell protein content (mg). The pathway illustrations show the carbon flux fueled by the 14C-labeled palmitic acid. The filled and
open circles represent radiolabeled (filled, 14C) and non-labeled (open) carbons, released as CO2 under the respective conditions. (D) Correlation analysis (Spearman)
of data obtained from multiple conditions of metabolic adaptation. PDK4 mRNA expression was analyzed relative to fatty acid oxidation and CPT1A expression. The
oxidation data are shown as mean ± SD of 4–8 replicates, from one representative for three separate experiments. Statistical comparisons was performed by ANOVA.
*p < .05, **p < .01, ***p < .001, ****p < .0001.
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interact to mediate adaptations to changed metabolic needs or condi-
tions (e.g. due to activity or diet). For instance, increased release of free
fatty acids from adipose tissue under fasting would be expected to in-
fluence metabolism in relevant tissues, partly through ligand activation
of PPARs. The effects of such events will vary depending on tissue and
cell type. Therefore, it was interesting to find that increased PDK4 ex-
pression was a rather consistent sign of increased fatty acid oxidation
throughout this study. Measuring PDK4 may be relevant in clinical in-
vestigations, as exemplified by the finding that upregulated PDK4 ex-
pression in blood cells was associated with impaired PDH function in
ME/CFS patients (Fluge et al., 2016), which may involve adaptations of
fatty acid oxidation (Naviaux et al., 2016; Germain et al., 2017). Fur-
thermore, diurnal variation in PDK4 expression in blood cells was re-
cently reported to be associated with plasma free fatty acid levels,
supporting that this mirrors an important aspect of metabolic fuel
switching (Yamaguchi et al., 2018). Hence, based on these findings, and
supported by the current literature, upregulated PDK4 expression ap-
pears as a sensitive marker for metabolic adaptations involving in-
creased rates of mitochondrial fatty acid oxidation.
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